73 FR 223 pgs. 68332-68333 - Exceptions or Alternatives to Labeling Requirements for Products Held by the Strategic National Stockpile; Technical Amendment
Type: RULEVolume: 73Number: 223Pages: 68332 - 68333
Docket number: [Docket No. FDA-2006-N-0364] (formerly Docket No. 2006N-0466)
FR document: [FR Doc. E8-27254 Filed 11-17-08; 8:45 am]
Agency: Health and Human Services Department
Sub Agency: Food and Drug Administration
Official PDF Version: PDF Version
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Part 601
[Docket No. FDA-2006-N-0364] (formerly Docket No. 2006N-0466)
Exceptions or Alternatives to Labeling Requirements for Products Held by the Strategic National Stockpile; Technical Amendment
AGENCY:
Food and Drug Administration, HHS.
ACTION:
Final rule; technical amendment.
SUMMARY:
The Food and Drug Administration (FDA) is amending the biologics regulations to reincorporate a regulation that was inadvertently removed. This action is being taken to correct the regulations.
DATES:
This rule is effective November 18, 2008.
FOR FURTHER INFORMATION CONTACT:
Tiffany J. Brown, Center for Biologics Evaluation and Research (HFM-17), Food and Drug Administration, 1401 Rockville Pike, suite 200N, Rockville, MD 20852-1448, 301-827-6210.
SUPPLEMENTARY INFORMATION:
FDA has discovered that an error appeared in the agency's codified regulations for part 601 (21 CFR part 601). In the Federal Register of December 28, 2007 (72 FR 73589), FDA published an interim final rule that inadvertently revised § 601.12(f)(3)(i)(D) (21 CFR 601.12(f)(3)(i)(D)) instead of adding a new paragraph, § 601.12(f)(3)(i)(E). Accordingly, § 601.12(f)(3)(i)(D), which was added in the Federal Register of January 24, 2006 (71 FR 3922), is being reincorporated into the regulations to replace current § 601.12(f)(3)(i)(D); current § 601.12(f)(3)(i)(D) is being redesignated as § 601.12(f)(3)(i)(E). This document corrects the errors described previously. Publication of this document constitutes final action under the Administrative Procedure Act (5 U.S.C. 553). FDA has determined that notice and public comment are unnecessary because this amendment is nonsubstantive.
List of Subjects in 21 CFR Part 601
Administrative practice and procedure, Biologics, Confidential business information.
Therefore, under the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act, and under authority delegated to the Commissioner of Food and Drugs, 21 CFR part 601 is amended as follows:
PART 601-LICENSING
1. The authority citation for 21 CFR part 601 continues to read as follows:
Authority:
15 U.S.C. 1451-1561; 21 U.S.C. 321, 351, 352, 353, 355, 356b, 360, 360c-360f, 360h-360j, 371, 374, 379e, 381; 42 U.S.C. 216, 241, 262, 263, 264; sec 122, Pub. L. 105-115, 111 Stat. 2322 (21 U.S.C. 355 note).
2. In § 601.12, redesignate paragraph (f)(3)(i)(D) as paragraph (f)(3)(i)(E) and add new paragraph (f)(3)(i)(D) to read as follows:
§ 601.12 Changes to an approved application.
(f) * * *
(3)(i) * * *
(D) A change to the information required in § 201.57(a) of this chapter as follows:
( 1 ) Removal of a listed section(s) specified in § 201.57(a)(5) of this chapter; and
( 2 ) Changes to the most recent revision date of the labeling as specified in § 201.57(a)(15) of this chapter.
Dated: November 10, 2008.
Jeffrey Shuren,
Associate Commissioner for Policy and Planning.
[FR Doc. E8-27254 Filed 11-17-08; 8:45 am]
BILLING CODE 4160-01-S